PL2696848T3 - Liofilizowane nanozawiesiny leków - Google Patents

Liofilizowane nanozawiesiny leków

Info

Publication number
PL2696848T3
PL2696848T3 PL12713187T PL12713187T PL2696848T3 PL 2696848 T3 PL2696848 T3 PL 2696848T3 PL 12713187 T PL12713187 T PL 12713187T PL 12713187 T PL12713187 T PL 12713187T PL 2696848 T3 PL2696848 T3 PL 2696848T3
Authority
PL
Poland
Prior art keywords
freeze dried
dried drug
drug nanosuspensions
nanosuspensions
freeze
Prior art date
Application number
PL12713187T
Other languages
English (en)
Inventor
Sabine Karine Katrien Inghelbrecht
Henning GIESELER
Jakob Andreas BEIROWSKI
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of PL2696848T3 publication Critical patent/PL2696848T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12713187T 2011-04-15 2012-04-13 Liofilizowane nanozawiesiny leków PL2696848T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161475811P 2011-04-15 2011-04-15
EP12713187.8A EP2696848B1 (en) 2011-04-15 2012-04-13 Freeze dried drug nanosuspensions
PCT/EP2012/056818 WO2012140220A1 (en) 2011-04-15 2012-04-13 Freeze dried drug nanosuspensions

Publications (1)

Publication Number Publication Date
PL2696848T3 true PL2696848T3 (pl) 2020-12-28

Family

ID=45937395

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12713187T PL2696848T3 (pl) 2011-04-15 2012-04-13 Liofilizowane nanozawiesiny leków

Country Status (21)

Country Link
US (5) US20140038996A1 (pl)
EP (2) EP3799860A1 (pl)
JP (1) JP6161593B2 (pl)
CN (2) CN103764117A (pl)
AU (1) AU2012241726C1 (pl)
BR (1) BR112013026363B1 (pl)
CA (1) CA2832410C (pl)
CY (1) CY1123434T1 (pl)
DK (1) DK2696848T3 (pl)
ES (1) ES2823805T3 (pl)
HK (1) HK1257447A1 (pl)
HR (1) HRP20201241T1 (pl)
HU (1) HUE050970T2 (pl)
LT (1) LT2696848T (pl)
MX (1) MX362344B (pl)
PL (1) PL2696848T3 (pl)
PT (1) PT2696848T (pl)
RS (1) RS60651B1 (pl)
RU (1) RU2643062C2 (pl)
SI (1) SI2696848T1 (pl)
WO (1) WO2012140220A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024230C (en) 2011-04-28 2022-10-18 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
CA2907415C (en) * 2013-03-15 2022-04-05 Iceutica Inc. Abiraterone acetate formulation
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
CN105902496B (zh) * 2016-04-18 2019-10-25 沈阳药科大学 一种纳米混悬液固体化过程的处理方法
US10507165B2 (en) * 2017-05-31 2019-12-17 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using same
RU2665383C9 (ru) * 2017-06-22 2019-07-23 Общество с ограниченной ответственностью "Вириом" Фармацевтическая наносуспензия для терапии ВИЧ-инфекции
JP7102500B2 (ja) 2017-07-14 2022-07-19 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物
RU2721562C1 (ru) * 2019-06-04 2020-05-20 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ загрузки неорганических наночастиц или органических молекул в пористые частицы микронного или субмикронного размера
CN111149795A (zh) * 2020-01-14 2020-05-15 成都艾伟孚生物科技有限公司 一种冷冻保护剂及其应用和一种精子冷冻液及其制备方法
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
WO2021222545A1 (en) * 2020-04-29 2021-11-04 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
CN115776882A (zh) 2020-07-09 2023-03-10 詹森药业有限公司 长效配制品
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物
AU2021303490A1 (en) 2020-07-09 2023-03-09 Janssen Pharmaceutica Nv Long-acting formulations
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
JP6886551B1 (ja) * 2020-11-06 2021-06-16 医療法人祥和会 歯科用の局所麻酔液
CN112641950B (zh) * 2021-01-12 2022-12-16 北京德立福瑞医药科技有限公司 含有难溶性抗肿瘤活性剂的药物组合物及其制备方法
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations
WO2023154454A1 (en) * 2022-02-10 2023-08-17 Soligenix, Inc. Telmisartan nanosuspension for therapy of respiratory infections and methods of making and using same
WO2023203257A1 (en) * 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
CN116115621A (zh) * 2022-10-31 2023-05-16 广州鹏兴医药科技有限公司 氢氯噻嗪组合物及其制备方法及氢氯噻嗪微针透皮贴剂
CN116919898B (zh) * 2023-09-15 2023-12-19 北京星辉再生科技有限责任公司 米诺地尔纳晶混悬液组合物、米诺地尔纳晶混悬液及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US20050004049A1 (en) 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1569623B1 (en) 2002-12-13 2008-10-15 Jagotec Ag A topical nanoparticulate spironolactone formulation
RU2331424C2 (ru) * 2002-12-13 2008-08-20 Джеготек Аг Топический состав, содержащий наночастицы спиронолактона
RU2407529C2 (ru) * 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
ES2564241T3 (es) 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
WO2007147882A2 (en) * 2006-06-23 2007-12-27 Tibotec Pharmaceuticals Ltd. Aqueous suspensions of tmc278
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP5701057B2 (ja) * 2007-07-12 2015-04-15 ヤンセン サイエンシズ アイルランド ユーシー (e)4−[[4−[[4−(2−シアノエテニル)−2,6−ジメチルフェニル]アミノ]−2−ピリミジニル]アミノ]ベンゾニトリルの結晶形
US8161810B2 (en) 2008-01-29 2012-04-24 Carefusion 303, Inc. Syringe imaging systems
CN101283982B (zh) * 2008-06-03 2010-06-02 南京工业大学 非诺贝特纳米混悬剂及其制备方法
CN101904820A (zh) * 2009-06-02 2010-12-08 姜玲敏 槲皮素纳米混悬剂冻干组合物及其制备方法和应用
CN101612131B (zh) * 2009-07-17 2011-09-14 郑州大学 2-甲氧基雌二醇纳米混悬剂冻干粉及其制备方法
CN101953808B (zh) * 2010-10-13 2013-03-13 厦门大学 抗肿瘤化合物去乙酰真菌环氧乙酯注射剂及其制备方法

Also Published As

Publication number Publication date
SI2696848T1 (sl) 2020-10-30
US11819502B2 (en) 2023-11-21
PT2696848T (pt) 2020-09-03
CY1123434T1 (el) 2021-12-31
EP3799860A1 (en) 2021-04-07
AU2012241726B2 (en) 2017-04-27
LT2696848T (lt) 2020-09-10
US10166231B2 (en) 2019-01-01
US20160317534A1 (en) 2016-11-03
BR112013026363B1 (pt) 2021-10-13
MX362344B (es) 2019-01-11
DK2696848T3 (da) 2020-10-12
RU2013150803A (ru) 2015-05-20
CA2832410C (en) 2019-07-23
CN103764117A (zh) 2014-04-30
CN108210469A (zh) 2018-06-29
CA2832410A1 (en) 2012-10-18
HK1257447A1 (zh) 2019-10-18
JP6161593B2 (ja) 2017-07-12
WO2012140220A1 (en) 2012-10-18
US11389448B2 (en) 2022-07-19
AU2012241726C1 (en) 2017-09-14
RS60651B1 (sr) 2020-09-30
BR112013026363A2 (pt) 2016-12-27
MX2013011985A (es) 2013-11-04
US20240148726A1 (en) 2024-05-09
AU2012241726A1 (en) 2013-10-24
US20140038996A1 (en) 2014-02-06
US20190076428A1 (en) 2019-03-14
RU2643062C2 (ru) 2018-01-30
EP2696848A1 (en) 2014-02-19
JP2014515021A (ja) 2014-06-26
EP2696848B1 (en) 2020-07-22
HUE050970T2 (hu) 2021-01-28
HRP20201241T1 (hr) 2020-11-27
ES2823805T3 (es) 2021-05-10
US20220409616A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
HK1257447A1 (zh) 凍干藥物納米混懸劑
PL2776416T3 (pl) Związki farmaceutyczne
GB201008005D0 (en) Pharmaceutical compounds
SG10201604667YA (en) Pharmaceutical preparation
HK1201534A1 (en) Pharmaceutical compounds
GB201119799D0 (en) Pharmaceutical compounds
GB201020161D0 (en) Pharmaceutical compounds
GB201105298D0 (en) Pharmaceutical preparation
PL2768485T3 (pl) Nanozawiesina farmaceutyczna
EP2731610A4 (en) PHARMACEUTICAL COMBINATION
GB201118876D0 (en) Pharmaceutical compounds
GB201113163D0 (en) Pharmaceutical compounds
AU343043S (en) Herb chopper
PL2691119T3 (pl) Preparat farmaceutyczny
PL2394638T3 (pl) Nowe połączenia farmaceutyczne
HRP20141173T1 (hr) Medikament koji sadrži miramistin
ZA201301851B (en) Pharmaceutical combinations
GB201119796D0 (en) Pharmaceutical comopounds
GB201119942D0 (en) Better freeze drying device
GB201119941D0 (en) Improved freeze drying device
GB201118875D0 (en) Pharmaceutical compounds
GB201118874D0 (en) Pharmaceutical compounds
GB201117359D0 (en) Pharmaceutical compounds
GB201105026D0 (en) Pharmaceutical compounds
GB201120735D0 (en) New pharmaceutical uses